Recent advances in the treatment of chronic lymphocytic leukemia: defining the role of intravenous immunoglobulin.
Besa
E C
EC
Department of Medicine, Medical College of Pennsylvania, Philadelphia 19129.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000361:Agammaglobulinemia / Q000209:etiology / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D000477:Alkylating Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000209:etiology / Q000628:therapy; D014408:Biomarkers, Tumor; D002869:Chromosome Aberrations; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D007239:Infections / Q000209:etiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care
D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D014408:Biomarkers, Tumor; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors